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Abstract: WNT1-inducible signaling pathway protein-1 (WISP-1) is an extracellular matrix-related protein that plays 
multiple roles in cellular physiology and pathology. Accumulating evidence shows that WISP-1 is involved in the 
process underlying fibrotic diseases. However, the correlation between WISP-1 and renal fibrosis is unknown. In this 
study, we hypothesized that WISP-1 levels might be correlated with renal fibrosis and could be used as a noninvasive 
biomarker to screen for renal fibrosis in patients with chronic kidney disease (CKD). We first measured the WISP-1 
expression levels using a transforming growth factor-β (TGF-β)-induced renal fibrosis tubular epithelial cell (TEC) 
model and a mouse model of obstructive nephropathy. We then evaluated the correlation between serum WISP-1 
levels and fibrosis scores in biopsy-proven renal fibrosis of patients with CKD. Based on the findings from both in vivo 
and in vitro studies, the levels of WISP-1 and fibrotic parameters (collagen I, fibronectin and α-smooth muscle actin) 
were significantly increased in the fibrotic models. Consistently, patients with focal proliferative IgA nephropathy, 
focal segmental glomerular sclerosis and diabetic nephropathy displayed markedly elevated serum WISP-1 levels 
and fibrosis scores of renal biopsies compared with normal subjects and patients with minimal change disease 
(P<0.05). Importantly, the serum WISP-1 levels were positively correlated with fibrosis scores in the renal biopsies of 
these patients (r=0.475, P=0.0001). Thus, serum WISP-1 levels may be used as a potential noninvasive biomarker 
of renal fibrosis in patients with CKD.
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Introduction
The prevalence of chronic kidney disease (CKD) 
has been estimated to be 10.8% in China [1] 
and 11.6% in the USA [2]. CKD is becoming a 
major global public health issue and is causing 
a substantial social and economic burden glob-
ally [3, 4]. According to data from the United 
State Renal Data System (USRDS) 2016 Annual 
Report, the annual expenditure on CKD among 
patients 65 and older is estimated to be US$50 
billion, accounting for 20% of the annual Me- 
dicare costs of this age group. Moreover, an 
additional cost of US$32.8 billion was spent on 
end-stage renal disease (ESRD) (https://www.
usrds.org/).
Renal fibrosis is a common pathogenesis of 
various CKDs, such as IgA nephropathy (IgAN) 
[5, 6], primary focal segmental glomerular scle-
rosis (FSGS) [7] and diabetic nephropathy (DN) 
[8-12]. Massive fibrosis in renal glomeruli and/
or tubules induces a deterioration of renal func-
tion, ultimately causing ESRD. Early detection 
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of renal fibrosis may lead to better diseases 
outcomes for patients and reduce social and 
economic burdens. In current clinical practice, 
renal fibrosis must be examined via a renal 
biopsy, an inconvenient and invasive proce-
dure. In this study, we aimed to identify a nonin-
vasive biomarker of renal fibrosis for the early 
detection and monitoring of fibrotic renal 
diseases.
WNT1-inducible signaling pathway protein 1 
(WISP-1), also known as CCN4/ELM-1, is an 
extracellular matrix-related protein. WISP-1 
plays multiple roles in cellular and pathogenic 
processes including cell proliferation, migra-
tion, adhesion, angiogenesis and tumorigene-
sis [13, 14]. Previous studies have shown that 
WISP-1 is strongly correlated with fibrotic dis-
eases, such as lung, heart and liver fibrosis [15-
17]. WISP-1 is a prohypertrophic and profibrotic 
growth factor that promotes cardiomyocyte 
hypertrophy, fibroblast proliferation and extra-
cellular matrix (ECM) deposition [18]. Elevated 
WISP-1 levels have been observed in patients 
with idiopathic pulmonary fibrosis, and the 
blockade of the WISP-1 protein using a neutral-
izing antibody resulted in the remarkable atten-
uation of fibrosis in a mouse model of bleomy-
cin-induced pulmonary fibrosis [16]. Moreover, 
the blockade of WISP-1 using a neutralizing 
monoclonal antibody attenuated chronic liver 
injury and hepatic fibrosis in a carbon tetrachlo-
ride (CCl4)-treated mouse model [19]. However, 
whether WISP-1 is correlated with renal fibrosis 
in patients with CKD is unknown. In the present 
study, we hypothesize that the serum WISP-1 
levels are increased in patients with renal 
fibrotic diseases and potentially serves as a 
biomarker of renal fibrosis. Indeed, both the in 
vivo and in vitro studies revealed that WISP-1 
expression was elevated with increased levels 
of fibrotic parameters, including collagen I, 
fibronectin and α-smooth muscle actin. We also 
found that the serum WISP-1 levels were posi-
tively correlated with the severity of renal fibro-
sis in patients with CKD. Our study indicates 
that WISP-1 is a potential noninvasive biomark-
er for the detection of renal fibrosis. 
Materials and methods
Patients and controls 
Renal biopsies were obtained from a cohort of 
96 patients with CKD who were hospitalized in 
the Department of Nephrology of Sichuan 
Provincial People’s Hospital between 2010 and 
2015. Seventy-seven patients with CKD were 
diagnosed with renal fibrosis based on a renal 
biopsy, including 35 patients with focal prolif-
erative IgAN, 18 with FSGS, and 24 with DN. 
Nineteen biopsies showing minimal change dis-
eases (MCD) without renal fibrosis were used 
as the minimal positive controls, and 18 healthy 
age- and gender-matched volunteers served as 
the normal controls. According to the Kidney 
Disease: Improving Global Outcomes (KDIGO) 
2012 guidelines (http://kdigo.org/home/gui- 
delines/), CKD is defined as abnormalities of 
kidney structure or functions that are present 
for ≥3 months with implications for health. The 
renal biopsies were independently examined by 
two senior pathologists in Sichuan Provincial 
People’s Hospital. The included patients had no 
history of receiving corticosteroids or other 
immunosuppressive therapy for kidney diseas-
es when they underwent the biopsy examina-
tions and had no systemic diseases, such as 
rheumatoid arthritis, pulmonary fibrosis or liver 
cirrhosis. The study protocol was approved by 
the Medical Ethics Committee of the Sichuan 
Academy of Medical Sciences and Sichuan 
Provincial People’s Hospital (No. 2014 Natural 
Science (04)).
Demographic and laboratory data
Patient demographic data, including gender, 
age, and blood pressure were collected at 
admission. Serum and urine samples were 
obtained from the patients and healthy volun-
teers. Laboratory data, including the hemoglo-
bin, glucose, albumin, blood urea nitrogen 
(BUN), serum creatinine (Scr), and uric acid lev-
els, 24-hour urinary protein excretion and the 
estimated glomerular filtration rate (eGFR) 
were examined at the Clinical Laboratory 
Department of Sichuan Provincial People’s 
Hospital. Serum creatinine levels were mea-
sured using an enzymatic method and recali-
brated to standardized creatinine measure-
ments. The eGFR was calculated using the 
Chronic Kidney Disease Epidemiology Coll- 
aboration (CKD-EPI) creatinine equation [2]. 
WISP-1 ELISA analysis
The serum WISP-1 levels in each group were 
determined using an ELISA kit (Abcam, 
Cambridge, UK), according to the manufactur-
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er’s instructions. Prior to examination, all serum 
samples from each group were collected and 
stored at -80°C. Each sample was measured in 
duplicate simultaneously.
Histology and immunohistochemistry
Histological and immunohistochemical analy-
ses were performed on methyl Carnoy’s-fixed, 
paraffin-embedded, 3-μm-thick tissue sections 
as previously described [9, 10, 20-23]. Changes 
in renal morphology were assessed by periodic 
acid-Schiff (PAS) and Masson’s trichrome stain-
ing (Trichrome stain kit, ScyTek Laboratories, 
West Logan, UT, USA) according to the manu-
facturer’s instructions. A microwave-based an- 
tigen retrieval technique was used to immunos-
tain the sections. Primary antibodies against 
WISP-1 (Abcam, Cambridge, UK), collagen I 
(Abcam, Cambridge, UK), fibronectin (Abcam, 
Cambridge, UK) and α-smooth muscle actin 
(α-SMA) (Proteintech, Chicago, IL, USA) were 
incubated with the tissue sections overnight at 
4°C. An isotype-matched rabbit IgG (R&D 
Systems, Minneapolis, MN, USA) was used as a 
negative control throughout the study. After 
washing with PBS, the tissue sections were 
incubated with horseradish peroxidase-labeled 
secondary antibodies (Dako, Carpinteria, CA, 
USA) at room temperature for 1-2 hours, fol-
lowed by the development of a brown color 
using diaminobenzidine. All tissue sections 
were counterstained with hematoxylin and 
eosin to visualize the nuclei. Changes in both 
histology and immunohistochemistry were 
quantitatively analyzed using the Image-Pro 
Plus 7.0 quantitative imaging program (Media 
Cybernetics, Bethesda, MD, USA) as previously 
described [9, 10, 20-23]. Positive signals were 
quantitatively measured in both the glomeruli 
and the tubulointerstitium area and are 
expressed as percentages of the examined 
areas.
Cell culture and treatment
A normal rat tubular epithelial cell line (TEC) 
(NRK52E, ATCC, USA) was maintained in Dul- 
becco’s Modified Eagle’s Medium with low 
glucose (DMEM/LG) culture medium contain- 
ing 5% fetal bovine serum and a 0.1% antibiot-
ic-antimycotic solution (Gibco®, Life Technol- 
ogies, Carlsbad, CA, USA) in 75-cm2 flasks in a 
37°C incubator with 5% CO2. To study WISP-1 
expression during renal fibrosis in vitro, TECs 
were treated with 2 ng/ml human transfor- 
ming growth factor (TGF)-β1 (R&D Systems, 
Minneapolis, MN, USA) in serum-free medium 
for 0, 6, 12 and 24 hours, based on the results 
of our preliminary studies [22, 23]. The WISP-1 
and renal fibrosis markers levels were also 
analyzed by real-time RT-PCR and western 
blotting.
Mouse model of obstructive kidney disease 
Twenty male C57BL/6 mice (20-22 g body 
weight, 10 weeks old) were purchased from the 
Laboratory Animal Services Center, Sichuan 
Academy of Medical Sciences and Sichuan 
Provincial People’s Hospital, China. A unilateral 
ureteral obstruction (UUO) renal fibrosis model 
was created by left ureteral ligation as previ-
ously described [20, 22, 23]. A group of ten 
age-matched mice was used as the sham con-
trol group. Sham mice received the same pro-
cedure as the mice in the UUO group, but with 
the exception that the left ureter was not ligat-
ed. All mice were housed under controlled envi-
ronmental conditions (23°C) under a 12-hr 
light/dark cycle. The experimental mice were 
sacrificed on day 7 after UUO, and the serum 
and kidney tissues were collected for further 
analysis. The experimental procedures were 
approved by the medical ethics committees of 
Sichuan Academy of Medical Sciences and 
Sichuan Provincial People’s Hospital, China, 
and the experiments were performed in accor-
dance with the guidelines provided by the 
National Institutes of Health for the use of ani-
mals in laboratory experiments.
Real-time (RT)-PCR and gene expression 
analysis
Total RNA was isolated from the cultured cells 
and renal cortex using the TRIzol reagent 
(Invitrogen, CA, USA) according to the manufac-
turer’s instructions. cDNA was synthesized us- 
ing a reverse transcriptase kit (Takara, Japan). 
The mRNA expression levels of fibrotic markers 
(collagen I, fibronectin, and α-SMA) were mea-
sured by real-time PCR. The WISP-1 primers 
used were as follows: forward: 5’-CGCCCG- 
AGGTACGCAATAG-3’ and reverse: 5’-GCAGTT- 
GGGTTGGAAGGACT-3’. Other primers were 
used as previously described [20, 22, 23]. The 
housekeeping gene GAPDH was used as the 
internal control. The expression levels of the 
target genes were calculated using the ΔΔCt 
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Figure 1. The levels of WISP-1 and fibrosis markers in TGF-β-treated TECs were assessed using real-time PCR and 
western blot analyses. (A) The levels of collagen I, (B) fibronectin, (C) α-SMA and (D) WISP-1 are increased in TECs in 
response to the TGF-β treatment (2 ng/ml for 24 hours), as determined by real-time PCR analyses. (E) The protein 
levels of collagen I, (F) fibronectin and (G) WISP-1 are increased in TECs in response to the TGF-β treatment (2 ng/
ml for 24 hours), as determined by western blot analyses. (H) Western blots of collagen I, fibronectin, α-SMA and 
WISP-1 in TECs treated with or without TGF-β (2 ng/ml for 24 hours). α-SMA, α-smooth muscle actin; Col I, collagen 
I; FN, fibronectin; NT, not treated with TGF-β; TGF, transforming growth factor; TECs, tubular epithelial cells. *P<0.05, 
**P<0.01, ***P<0.001 compared with 0 h. #P<0.05, ##P<0.01, ###P<0.001 compared with NT.
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method. The results are presented as the mean 
± standard error of the mean (SEM).
fibrosis scores in biopsy tissues and the patient 
clinical parameters. A P<0.05 was considered 
Figure 2. Levels of WISP-1 and fibrotic markers in the obstructive kidney dis-
ease model were assessed using real-time PCR and western blot analyses. 
(A) Levels of collagen I, (B) fibronectin, (C) α-SMA and (D) WISP-1 mRNAs are 
significantly increased in UUO mice after 7 days compared to the sham mice 
according to the real-time PCR analysis. (E) Levels of collagen I, (F) fibronec- 
tin, (G) α-SMA and (H) WISP-1 proteins are significantly increased in the UUO 
mice after 7 days compared with the sham mice, as shown by western blot 
analyses. (I) Western blots for collagen I, fibronectin, α-SMA and WISP-1. α- 
SMA, α-smooth muscle actin; Col I, collagen I; FN, fibronectin; UUO, unilateral 
ureteral obstruction. **P<0.01, ***P<0.001 compared with the sham mice.
Western blot analysis
Protein was extracted from 
the mouse kidney tissues and 
experimental cells using ra- 
dioimmunoprecipitation ass- 
ay (RIPA) lysis buffer, and 
western blot analysis was per-
formed using a previously 
described method [9, 10, 
20-23]. Primary antibodies, 
against WISP-1 (Abcam, Ca- 
mbridge, UK), collagen I (Ab- 
cam, Cambridge, UK), fibro-
nectin (Abcam, Cambridge, 
UK), α-SMA (Proteintech, Ch- 
icago, IL, USA) and GAPDH 
(MAB374, Millipore, Billerica, 
MA, USA) were used in the 
study. After incubation with 
the primary antibody at 4°C 
overnight, the blotting mem-
brane was stained with the 
secondary antibody at room 
temperature for 2 hours. The 
protein signals were captured 
using an Image Quant LAS 
4000 mini system and quanti-
tatively analyzed using the 
ImageJ software (NIH). The 
protein levels were analyzed 
based on the ratio of the tar-
get proteins to GAPDH. The 
data are presented as the 
mean ± SEM.
Statistical analysis
Continuous variables are pre-
sented as the mean ± SEM or 
the median (interquartile ra- 
nge), and differences bet- 
ween groups were compared 
using Student’s t-test or one-
way analysis of variance (AN- 
OVA) with the S-N-K or Mann-
Whitney U test. Categorical 
data were compared using 
the Chi square test or Fisher’s 
exact test. Spearman’s or 
Pearson’s correlation analy- 
sis was used to analyze the 
correlations between serum 
WISP-1 expression, the renal 
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significant. The SPSS 19.0 statistical software 
was used to analyze the data.
Results
WISP-1 levels and fibrosis are increased in 
TGF-β-treated TEC
We examined the role of WISP-1 in the TGF-β-
induced fibrosis in TECs in vitro. Based on the 
results of the real-time PCR analysis, 2 ng/ml 
TGF-β induced fibrosis, as indicated by the 
increases in the levels of the fibrotic markers 
collagen I, fibronectin and α-SMA. As expected, 
WISP-1 expression was increased in a time-
dependent manner after TGF-β treatment and 
reached a maximum at 24 hours (Figure 1A-D). 
Consistent with this finding, the western blot 
analysis confirmed that the levels of both WISP-
1 and the fibrotic markers collagen I and fibro-
nectin were increased after 24 hours of TGF-β 
treatment (Figure 1E-H). Together, these results 
suggest that WISP-1 expression may correlate 
with fibrotic events.
WISP-1 levels and renal fibrosis are increased 
in the mouse model of obstructive kidney 
disease
To confirm the above findings, we performed an 
in vivo study in the UUO renal fibrotic disease 
model. As shown in Figure S1, the histological 
morphology of the UUO mice demonstrated 
typical hydronephrosis, fibrosis and inflamma-
tory cell infiltration. According to the immuno-
histochemical staining, the collagen I, fibronec-
tin, α-SMA and WISP-1 levels were significantly 
increased in mice with obstructive kidney dis-
eases compared to the sham mice, as shown in 
Figure S2. We then examined the protein levels 
of fibrotic markers and WISP-1 in the diseased 
and normal kidneys using real-time PCR and 
western blot analyses. As shown in Figure 2A-I, 
the levels of the collagen I, fibronectin and 
α-SMA mRNAs and proteins were significantly 
increased in the mice with obstructive kidney 
disease at 7 days compared with the sham 
mice. The elevated WISP-1 levels were consis-
tently and positively correlated with the chang-
es in the levels of fibrotic markers levels in the 
mice, suggesting that WISP-1 might be corre-
lated with renal fibrosis in patients with fibrotic 
kidney diseases. Next, we examined whether 
the serum WISP-1 levels correlated with the 
renal fibrosis scores in CKD patients.
Demographic and laboratory characteristics
Demographic and laboratory data from the 96 
patients with biopsy-proven kidney diseases 
(35 with IgAN, 18 with FSGS, 24 with DN and 
19 with MCD) were analyzed. Data from 18 
healthy age- and gender-matched volunteers 
were used as the normal control group. The 
demographic and laboratory characteristic of 
subjects are shown in Table 1. The systolic 
pressure was significantly higher in the patients 
with IgAN, DN and FSGS than in patients with 
MCD (P<0.01 or P<0.05) and the normal con-
trols (P<0.01). Patients with IgAN, DN, and 
FSGS had remarkably lower hemoglobin levels 
than patients with MCD (P<0.01). Patients with 
DN had significantly higher blood glucose levels 
than patients with MCD (P<0.01) and the nor-
mal controls (P<0.01). The serum albumin lev-
els were significantly lower in the patients with 
MCD, IgAN, DN and FSGS than in the normal 
controls (P<0.01) and were significantly higher 
in the patients with IgAN and DN compared to 
the patients with MCD (P<0.01). Patients with 
IgAN, DN and FSGS had significantly higher uric 
acid (P<0.01), BUN (P<0.01) and Scr levels 
(P<0.01), and a decreased eGFR (P<0.01) than 
the normal controls. The IgAN patients had sig-
nificantly lower 24-hour urinary protein excre-
tion levels than the MCD (P<0.01), FSGS 
(P<0.01) and DN (P<0.01) patients. The labora-
tory data indicated that the clinical manifesta-
tions of the patients were consistent with the 
biopsy-proven diagnoses. Next we examined 
WISP-1 levels in the serum and biopsy speci-
mens from patients with CKD.
Expression and localization of WISP-1 in pa-
tients with biopsy-proven CKD
The levels of glomerulosclerosis, tubulointersti-
tial fibrosis and collagen ECM deposition were 
measured using PAS and Masson’s trichrome 
staining. Biopsies of nontumor kidney tissue 
from patients with renal cell carcinoma served 
as negative controls. Renal fibrosis was 
observed in biopsies from patients with IgAN, 
DN and FSGS, but not in those from patients 
with MCD or the negative controls, as shown in 
Figure 3. WISP-1 levels were significantly ele-
vated in the biopsy tissues from patients with 
IgAN, DN and FSGS compared to the biopsy tis-
sues from the negative controls and patients 
with MCD (Figure 3). Additionally, the expres-
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Table 1. Demographic and laboratory characteristic
Normal control
(n=18)
MCD
(n=19)
IgAN
(n=35)
DN
(n=24)
FSGS
(n=18)
Low fibrosis group
Fibrosis <25%, (n=43)
High fibrosis group
Fibrosis ≥25%, (n=34)
Gender (M/F) 10/8 13/6 16/19 13/11 13/5 23/20 19/15
Age (years) 34 (28, 57) 22 (18, 36)** 37 (25, 44)## 66 (59, 80)**,##,cc 28 (19, 47)aa 39 (23, 51)## 34 (24, 43)#
SBP (mmHg) 112 (103, 123) 118 (104, 127) 130 (124, 152)**,## 164 (129, 180)**,# 136 (130, 146)**,## 132 (124, 141)**,## 145 (127, 155)**,##
DBP (mmHg) 68±10 74±12 84±14**,# 71±18bb 91±15**,## 82±15**,# 90±15**,##
Hemoglobin (g/l) 143±15 151±23 134±19## 111±22**,##,cc 131±26##,aa 132±22## 129±22*,##
Glucose (mmol/l) 4.82 (4.73, 5.15) 5.29 (4.37, 6.45) 5.09 (4.78, 5.71) 13.2 (9.29, 22.1)**,##,cc 5.17 (4.62, 6.22)aa 5.26 (4.77, 6.79) 5.09 (4.76, 6.15)
Albumin (g/l) 45.4 (43.9, 48.5) 20.9 (16.4, 26.2)** 39.6 (37.0, 43.7)**,## 36.0 (32.9, 41.5)**,##,c 27.8 (16.9, 40.3)**,cc 39.2 (28.1, 41.5)**,## 37.0 (33.6, 43.6)**,##
BUN (mmol/l) 4.8 (4.1, 6.1) 5.4 (3.9, 6.1) 6.3 (5.5, 8.3)**,## 10.9 (8.3, 23.5)**,##,cc 8.8 (5.6, 10.7)**,##,a 6.1 (5.3, 8.4)**,# 9.2 (6.4, 10.8)**,##,&&
Scr (μmol/l) 65.5 (58.2, 77.5) 68.9 (61.1, 84.8) 90.3 (63.0, 134.6)**,## 126.8 (95.2, 257.7)**,##,cc 143.7 (93.7, 215.4)**,##,c 87.8 (62.5, 104.9)*,# 148.9 (116.1, 199.2)**,##,&&
UA (mmol/l) 285 (244, 351) 381 (285, 468)* 385 (335, 521)** 422 (362, 597)** 464 (338, 495)** 367 (317, 470)** 472 (393, 523)**,#,&&
Urine Protein (g/24 hours) -- 3.47 (2.23, 5.48) 1.41 (0.96, 2.97)##,a 4.61 (2.97, 9.34)cc 4.69 (2.28, 14.68)cc 2.12 (1.00, 4.61) 2.36 (1.36, 8.50)
eGFR (ml/min/1.73m2) 102.3 (92.6, 114.2) 124.1 (86.2, 140.3) 65.9 (48.2, 104.9)**,##,a 47.9 (21.0, 55.4)**,##,cc 51.7 (29.1, 88.7)**,## 88.9 (53.5, 106.0)*,## 45.1 (32.5, 59.6)**,##,&&
SBP, systolic blood pressure; DBP, diastolic blood pressure; BUN, blood urea nitrogen; Scr, serum creatinine; UA, uric acid; eGFR, estimated glomerular filtration rate; MCD, minimal change disease; IgAN, IgA nephropathy; DN, diabetic ne-
phropathy; FSGS, focal segmental glomerulosclerosis. *p<0.05, **p<0.01 compared with the normal controls. #p<0.05, ##p<0.01 compared with patients with MCD. ap<0.05, aap<0.01 compared with patients with DN. bbp<0.01 compared with 
patients with FSGS. cp<0.05, ccp<0.01 compared with patients with IgAN. &&p<0.01 compared with the low fibrosis group (fibrosis <25%).
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sion of WISP-1 was mainly localized in the tubu-
lointerstitial areas where fibrosis occurred. 
These results suggested that WISP-1 was sig-
nificantly expressed in renal fibrosis biopsy tis-
Figure 3. Extracellular matrix deposition and WISP-1 expression in kidney tissues from patients with MCD, IgAN, 
DN and FSGS and the negative controls. Representative images of histological and immunohistochemical staining 
images. Renal fibrosis indices and WISP-1 levels are increased in renal biopsy tissues from patients with fibrotic 
diseased diseases (IgAN, DN, and FSGS) compared with patients with MCD (minimal positive control) and negative 
controls. DN, diabetic nephropathy; FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy; MCD, mini-
mal change disease; negative control, normal kidney tissues from patients with renal cell carcinoma; PAS, periodic 
acid-Schiff. Bars =50 μm.
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sues and might be correlated with kidney fibro-
sis in CKD patients. 
Serum WISP-1 levels are elevated in CKD 
patients
Because urinary WISP-1 levels are not detect-
able in the healthy subjects and patients with 
CKD, according to our preliminary results and 
other studies [24], we evaluated the serum 
WISP-1 levels in patients with CKD. As shown in 
Figure 4A, the serum WISP-1 levels in patients 
with IgAN (645.45 (503.95, 934.26) pg/ml), 
DN (700.36 (280.45, 840.52) pg/ml) and FSGS 
(664.81 (448.35, 893.74,) pg/ml) were signifi-
cantly higher than the levels observed in 
patients with MCD (506.82 (132.60, 612.52) 
pg/ml) and healthy subjects (377.93 (233.12, 
657.20) pg/ml) (all, P<0.05). However, no sig-
nificant differences in the serum WISP-1 levels 
were observed in the patients with IgAN, DN or 
FSGS (P>0.05). Based on these findings, serum 
WISP-1 levels do not represent a disease-spe-
cific marker (for IgAN, DN or FSGS), but instead 
are a potential biomarker that could be used in 
renal fibrosis screening. Therefore, we analyzed 
the correlation between the serum WISP-1 lev-
els and the fibrotic scores in these CKD 
patients.
Serum WISP-1 levels are correlated with the 
renal fibrosis severity in CKD biopsy tissues
To explore whether the serum WISP-1 levels 
were associated with the fibrosis severity, 77 
CKD patients (35 with IgAN, 18 with FSGS, and 
24 with DN) with biopsy-proven differential 
renal fibrosis scores were analyzed. As shown 
in Table 1, 43 patients displayed renal fibrosis 
in less than 25% of the tissue (low fibrosis 
group), and 34 patients displayed fibrosis in 
greater than 25% of the tissue (high fibrosis 
group). Laboratory parameters, including the 
BUN, Scr and uric acid levels and the eGFRs, 
significantly differed among groups 1 and 2 
and the controls. Thus, the severity of fibrosis 
significantly affected the renal function param-
eters (BUN, Scr and eGFR), consistent with the 
clinical observations. Next, we examined the 
serum WISP-1 levels in the two groups and the 
Figure 4. Serum WISP-1 levels in patients with re-
nal fibrotic diseases. A. The WISP-1 concentration 
is significantly higher in the sera from patients with 
IgAN, DN and FSGS than in the sera from patients 
with MCD and healthy subjects (the normal controls). 
B. The WISP-1 levels in the high fibrosis group (over 
25% of fibrosis) were significantly increased com-
pared with the low fibrosis group (less than 25% of 
fibrosis). *P<0.05, **P<0.01 compared with the nor-
mal controls. #P<0.05, ##P<0.01 compared with the 
MCD patients. &&P<0.01 compared with the high fi-
brosis group. DN, diabetic nephropathy; FSGS, focal 
segmental glomerulosclerosis; IgAN, IgA nephropa-
thy; MCD, minimal change disease. Low fibrosis 
group, patients had renal fibrosis in less than 25% of 
the tissue. High fibrosis group, patients had fibrosis 
in greater than 25% of the tissue.
Figure 5. The serum WISP-1 levels are positively cor-
related with the renal fibrosis scores in CKD patients. 
The WISP-1 expression levels in the serum were posi-
tively correlated with the renal fibrosis scores in the 
renal biopsy tissues from the CKD patients.
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correlation with their fibrosis scores. As shown 
in Figure 4B, the WISP-1 levels in the high fibro-
sis group (754.76 (498.78, 1149.62) pg/ml) 
were significantly increased compared with the 
low fibrosis group (645.45 (449.32, 902.84) 
pg/ml). Therefore, we further assessed the cor-
relations between the serum WISP-1 levels, the 
severity of fibrosis in the biopsy tissues and the 
laboratory parameters (including gender, age, 
blood pressure, hemoglobin, glucose, albumin, 
BUN, Scr, and uric acid levels, 24-hour urinary 
protein excretion and the eGFR) using Spe- 
arman’s or Pearson’s correlation analysis. The 
serum WISP-1 levels were positively correlated 
with the renal fibrosis scores (r=0.475, 
P=0.001) (Figure 5). No significant associa-
tions were observed between the serum WISP-
1 levels and the other parameters. Thus, the 
serum WISP-1 levels are closely correlated with 
the severity of renal fibrosis in patients with 
CKD.
Discussion
Renal fibrosis is a landmark of CKD and is char-
acterized by the excessive deposition of ECM in 
renal tissues, including marked increases in 
the levels of collagens I, III and IV, fibronectin 
and α-SMA. Currently, substantial efforts are 
devoted to monitoring the development and 
progression of renal fibrosis in patients with 
CKD. However, the assessment of renal fibrosis 
in patients with CKD requires a renal biopsy. 
Noninvasive biomarkers that can be used to 
screen for fibrosis in patients with CKD are 
urgently needed. The Wnt/β-catenin pathway is 
known to be linked to the pathogenesis of 
fibrotic disorders [25, 26]. WISP-1 is a down-
stream molecule of Wnt-1 and β-catenin that is 
induced by the Wnt-1 protein [13, 14]. In this 
study, we report for the first time that the WISP-
1 levels are elevated in the fibrotic kidney in 
vivo and in TGF-β-induced TEC fibrosis in vitro. 
Importantly, the WISP-1 levels in the sera are 
correlated with the severity of renal fibrosis in 
CKD patients. Our findings are consistent with 
other publications reporting increased WISP-1 
levels in fibrotic organs, including the lung, 
heart and liver [15-17]. Thus, WISP-1 repre-
sents a potential biomarker of fibrosis patients 
with various types of tissue or organ fibrosis.
Patients with CKD, including IgAN, DN and 
FSGS, are generally recruited to test the corre-
lation of the serum WISP-1 level with the fibro-
sis severity in renal biopsies. Progressive renal 
fibrosis is very common in patients with IgAN, 
DN and FSGS [5-12]. Conversely, patients with 
MCD have no fibrosis in the kidney but present 
large amounts of albumin in their urine. 
Therefore, in our study, the kidney tissues from 
patients with MCD, served as the minimal posi-
tive controls for renal fibrosis [27], and nontu-
mor kidney tissues from patients with renal cell 
carcinoma served as the negative controls. 
First, WISP-1 levels were significantly elevated 
in biopsy-proven fibrotic renal tissues (IgAN, DN 
and FSGS) compared to that in MCD and nontu-
mor tissues (the negative controls). Second, 
WISP-1 was primarily expressed in the tubuloin-
terstitium in the biopsied kidney tissues, which 
exhibited inflammatory cells infiltration during 
the fibrotic process. Renal fibrosis is a condi-
tion of repair and scarring, which usually 
accompanies an inflammatory response during 
kidney injury [9-12, 23, 28, 29], WISP-1 has 
been shown to play an important role in inflam-
mation in obese animals [30] and in animals 
with hepatic injuries [31]. Consistent with the 
findings from patients with CKD, high WISP-1 
levels were observed in the area with severe 
tubulointerstitial fibrosis in the UUO mouse 
model. Interestingly, WISP-1 expression was 
induced by exogenous TGF-β1 in rat tubular epi-
thelial (NRK52E) cells in vitro. The profibrotic 
growth factor TGF-β1 induces the expression of 
α-SMA and other collagen matrix components 
in TECs by promoting epithelial-mesenchymal 
transition (EMT) in NRK52E cells [32, 33]. In 
this study, the observed significant increases in 
WISP-1 and α-SMA expression in the TECs indi-
cate that WISP1 expression in tubular cells may 
depend on TGF-β1 via the EMT. Based on these 
findings, the fibrosis-related protein WISP-1 is 
correlated with renal fibrosis events in vitro, 
and in vivo in patients with CKD. 
Indeed, the serum WISP-1 levels were signifi-
cantly elevated in patients with IgAN, DN and 
FSGS compared to patients with MCD and the 
healthy subjects (the normal controls). However, 
no significant differences in the WISP-1 levels 
were found between the IgAN, DN and FSGS 
groups (P>0.05), suggesting that WISP-1 was 
not specific to the disease classification. Then, 
we grouped the patients according to renal 
fibrosis severity and examined the potential 
correlations between the serum WISP-1 levels, 
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fibrosis severity, renal functions and other labo-
ratory parameters. The serum WISP-1 levels 
were only positively correlated with the renal 
fibrosis severity. Thus, serum WISP-1 levels 
may serve as a noninvasive biomarker of renal 
fibrosis. 
The discovery of biomarkers for kidney diseas-
es has attracted increasing interest [34, 35]. 
The serum creatinine level and the eGFR are 
the most common renal function indices, used 
in clinical practice [36, 37]. These two indices 
are changed in patients with both acute kidney 
injury and CKD. Neutrophil gelatinase-associat-
ed lipocalin, cystatin C, N-acetyl-β-D-glucosa- 
minidase and kidney injury molecule-1 are 
potential biomarkers of early kidney injury [38-
40]. MicroRNAs (miRNAs) are also associated 
with kidney injury (e.g., miRNAs 15, 17, 21, 29, 
31, and 192) [9, 10, 23, 41, 42]. Metabolomic 
and proteomic biomarkers can potentially be 
used to measure the progression and severity 
of kidney disease as replacements for the 
microalbumin and BUN levels [43-45]. However, 
the discovery of biomarkers for CKD has been 
slow compared to acute kidney injury. To pro-
mote the discovery and validation of biomark-
ers for CKD, the National Institute of Diabetes 
and Digestive and Kidney Diseases has estab-
lished the CKD Biomarkers Consortium. Biopsy 
examination remains the best available app- 
roach to determine the presence and severity 
of renal fibrosis. However, this invasive proce-
dure is associated with increased risks of 
bleeding, pain and arteriovenous fistula in 
patients [46-48]. Our findings indicate that 
serum WISP-1 is a potential biomarker that can 
be used to determine the severity of renal fibro-
sis. The use of this marker would reduce the 
risks associated with biopsies in patients with 
CKD.
This study has some limitations. We did not test 
the sensitivity or specificity of the serum WISP-
1 levels as a biomarker of renal fibrosis. 
Rigorous validation of WISP-1 as a biomarker 
should be performed in the future. Our study 
did not examine whether WISP-1 was a causal 
mediator in fibrosis or a downstream molecule 
of renal fibrosis. Thus, the role of WISP-1 war-
rants further study.
In conclusion, to the best of our knowledge, the 
present study is the first to report that the 
serum WISP-1 levels are positively correlated 
with the renal fibrosis severity. Serum WISP-1 
may be a potential noninvasive biomarker for 
the detection of renal fibrosis in CKD patients.
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Figure S1. Renal fibrosis in UUO mice was measured using HE, PAS and Masson’s trichrome staining. Represen-
tative images of renal morphology in the UUO and sham mice. Extracellular matrix deposition was significantly 
increased in the tubulointerstitium of the obstructed kidney. HE, hematoxylin and eosin; PAS, periodic acid-Schiff; 
UUO, unilateral ureteral obstruction. Bars =50 μm. 
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Figure S2. Levels of WISP-1 and fibrotic markers in the UUO mice were measured using immunohistochemistry. Rep-
resentative images of immunohistochemical staining in UUO and sham mice. The WISP-1, fibronectin, collagen I and 
α-SMA expression levels are significantly increased in the mice with obstructed kidneys compared to the sham mice. 
α-SMA, α-smooth muscle actin; Col I, collagen I; FN, fibronectin; UUO, unilateral ureteral obstruction. ***P<0.001 
compared with the sham mice. Bars =50 μm.
